Raising Money for
We’re Making Progress!
Investing in migraine research is beginning to pay off. MRF funding has supported research that…
- Identified new chemical compounds and therapeutic targets which could provide leads for future drug development.
- Discovered that female sufferers of migraine with aura are at increased risk of stroke in later life.
- Revealed that opiates, which are sometimes used to treat migraine, can cause changes in the brain that last long after usage stops.
- Established a migraine-specific DNA library and searchable electronic database for use in future research.
- Identified five genes that are involved in the link between migraine and cardiovascular disease, particularly stroke.
- Identified a potential mechanism underlying opioid-induced medication overuse headaches, providing a novel target for drug development.
- Found that brief behavioral interventions, especially cognitive behavioral therapy, may reduce headache frequency and anxiety in children.
- Showed that prolonged frequent use of triptan medication, intended to relieve headaches, may in fact induce headaches.
- Uncovered startling deficits in the treatment of childhood migraine, notably treatment contrary to care guidelines, the over-prescribing of opioids, and significant under-treatment.
- Identified 24 different genetic mutations associated with familial hemiplegic migraine.
- Found that a high sensitivity to external stimuli predicts the effectiveness of amitriptyline in preventing migraine, opening the door to a more personalized approach to treatment.
- Revealed the potential of immunotherapy as a migraine treatment.
- Discovered ground-breaking information about BDNF, a protein that could cause pain hypersensitivity in migraine.
- Demonstrated the promise of a brief behavioral sleep intervention for migraine patients, suggesting that directly treating co-occurring insomnia may improve migraine itself.